A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovascularizstion Secondary to Age-related Macular Degeneration

Trial Profile

A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovascularizstion Secondary to Age-related Macular Degeneration

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2015

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Adverse reactions; Registrational
  • Acronyms SUSTAIN
  • Sponsors Novartis
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 30 Oct 2008
    • 04 Oct 2007
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top